Do Wall Street Analysts Like Marsh & McLennan Stock?

Core Insights - Marsh & McLennan Companies, Inc. (MRSH) has a market cap of $83.8 billion and operates in insurance brokerage, reinsurance, risk management, and consulting services globally [1] - The company has experienced a decline in share price, lagging behind the S&P 500 Index and the State Street Financial Select Sector SPDR Fund [2] - MRSH reported a revenue of $6.6 billion for fiscal Q4 2025, reflecting a 9% year-over-year increase, with adjusted operating income rising 12% to $1.6 billion [4] - Analysts project a 6.1% growth in MRSH's EPS for the current year, with a consensus rating of "Moderate Buy" among 25 analysts [5] - Cantor Fitzgerald raised its price target for MRSH to $212, maintaining an "Overweight" rating based on strong Q4 results [7] Financial Performance - MRSH's revenue for Q4 2025 was $6.6 billion, marking a 9% increase year-over-year, with underlying growth of 4% [4] - Adjusted operating income increased by 12% to $1.6 billion, indicating margin expansion [4] - Adjusted EPS rose by 10% to $2.12, aided by favorable tax and foreign exchange impacts [4] Analyst Ratings - The consensus among 25 analysts is a "Moderate Buy," with ratings including seven "Strong Buy," one "Moderate Buy," 16 "Holds," and one "Moderate Sell" [5] - The configuration of analyst ratings has improved compared to two months ago, with a bullish outlook [6] Market Comparison - MRSH shares have declined 23.1% over the past year, while the S&P 500 Index increased by 14.4% [2] - In 2026, MRSH's stock dipped 5.5%, compared to a 1.4% advance in the S&P 500 [2] - The State Street Financial Select Sector SPDR Fund has risen 4.2% over the past year, indicating stronger performance compared to MRSH [2]